BioNTech Up Nearly 5% After Hours as Coronavirus Vaccine Candidate Selected to Advance
July 27 2020 - 6:19PM
Dow Jones News
By Josh Beckerman
Pfizer Inc. shares rose 1.6% to $38.15 after hours, while
BioNTech SE American depositary shares increased nearly 5% to
$90.65 as the companies selected a coronavirus vaccine candidate to
advance into a Phase 2/3 study.
The companies, which have studied multiple BNT162 RNA vaccine
candidates, will advance BNT162b2 at a 30 ug dose level in a
two-dose regimen.
Last week, the companies said the U.S. government agreed to pay
$1.95 billion upon receiving the first 100 million doses of a
vaccine in the BNT162 program.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
July 27, 2020 18:04 ET (22:04 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024
